Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were eligible for inclusion in the main analysis. Non-randomised controlled trials were eligible only for the sensitivity analysis.
Specific interventions included in the review
Studies were included if they compared concurrent groups of patients receiving some form of IHD or CRRT. Studies were excluded if they involved multiple interventions in the study groups. Various techniques were used in the included studies.
Participants included in the review
Studies in adult patients with ARF who were treated in an ICU were eligible for inclusion. The characteristics of the participants in each of the included studies were not given.
Outcomes assessed in the review
The primary outcome of interest was mortality, either in-hospital or at ICU discharge. The secondary outcomes were renal death (death or dependence on dialysis at the end of the study) and dialysis dependence among survivors, at hospital or ICU discharge.
How were decisions on the relevance of primary studies made?
The authors did not state how the papers were selected for the review, or how many reviewers performed the selection.
Assessment of study quality
Study validity was assessed in terms of randomisation, concealment of allocation, and the use of an intention-to-treat analysis. The authors did not state how the papers were assessed for validity, or how many reviewers performed the validity assessment.
Data extraction
Two independent reviewers extracted the data using a standardised form, and resolved any discrepancies by consensus with a third reviewer. If insufficient data were given in the paper, additional information was sought from the trial investigator.
Data on mortality, renal death and dialysis dependence were extracted from the individual studies and used to calculate a relative risk (RR), using intention-to-treat when possible. If both in-hospital and ICU discharge mortality rates were given then in-hospital rates were used. The Baseline Acute Physiology and Chronic Health Evaluation II (APACHE II) scores and the IHD and CRRT techniques used (including membrane and dose) were also noted.
Methods of synthesis
How were the studies combined?
The results from the individual studies were combined using fixed-and random-effects (DerSimonian and Laird) metaanalyses. The RR results were presented along with 95% confidence intervals (CIs).
The possibility of publication bias was investigated using the fail-safe N technique for RCTs and funnel plots for nonrandomised trials.
How were differences between studies investigated?
The homogeneity of the included studies was assessed statistically using the Cochran Q test and through visual examination of the distribution of mortality rates for IHD and CRRT. Sensitivity analyses were performed on the basis of study quality (randomised or non-randomised), the year the study was conducted and the CRRT technique used (haemodialysis, haemofiltration, or haemodiafiltration). Meta-regression was used as a formal test of interaction, and was also used to test for interaction between baseline severity according to the APACHE II score and mortality.
Results of the review
Six RCTs (n=624) were included in the main analysis. Twelve non-randomised studies (n=1,252) were included in additional sensitivity analyses.
Mortality.
There was no significant difference in survival between IHD and CRRT (RR 0.96, 95% CI: 0.85, 1.08, P=0.50) based on the 6 RCTS (fixed-effect). There was no evidence of statistically-significant heterogeneity across the studies (P=0.09). Similar results were obtained regardless of the inclusion of non-randomised studies, the CRRT technique used, the year of publication, or by controlling for baseline severity of illness. It was estimated that an additional trial with at least 1,250 patients would be required to detect a significant improvement (RR 1.2) in mortality with CRRT in comparison with IHD.
Renal recovery.
There was no statistically-significant difference in renal death between IHD and CRRT (RR 1.02, 95% CI: 0.89, 1.17, P=0.78) based on 371 patients in 4 RCTs (fixed-effect). There was no evidence of statistically-significant heterogeneity (Q=0.79, d.f.=3, P=0.85). Similarly, no statistically-significant difference in dialysis dependence was found (RR 1.19, 95% CI: 0.62, 2.27, P=0.60) and there was no evidence of statistical heterogeneity (Q=2.6, d.f.=3, P=0.78). It was estimated that, for renal death, the addition of a very large trial would be required to detect a significant difference between the therapies (number of patients provided). In contrast, one additional trial with 190 patients would be needed to show a statistically-significant difference in dialysis dependence in favour of CRRT if that trial showed around 50% reduction in dialysis dependence with CRRT.
